MaxCyte ovarian cancer peritoneal mesothelioma

MaxCyte receives FDA approval to start Phase I study of MCY-M11

MaxCyte has received investigational new drug (IND) approval from the US Food and Drug Administration (FDA) to initiate a Phase…